Home LiteratureArticle Details
PMID: 30310240 Published · ppublish English Journal Article

Potent HIV-1 Protease Inhibitors: Stereoselective Synthesis of a Dipeptide Mimic.

The Journal of organic chemistry ·Vol. 58 ·No. 5 ·1993-02-00 ·Pages 1025-1029

Ghosh AK, McKee SP, Thompson WJ, Darke PL, Zugay JC

Abstract

The synthesis of a differentially protected dipeptide mimic 10 in enantiomerically pure form is described. The key step involves the epimerization of the C-2 center of the lactone 4, hydrolysis and protection of the resulting hydroxy acid, followed by Curtius rearrangement to introduce the urethane functionality. The scope and versatility of this isostere has been demonstrated by its conversion to potent HIV-1 protease inhibitors with nanomolar potencies. Also, established through the synthesis of compound 13 and 14, the 3S hydroxyl configuration of the dipeptide isostere 1 is the preferred configuration for its potency. The present synthesis is efficient and provides an access to other dipeptide mimics with a great deal of structural diversity.

Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Ghosh Arun K
Department of Medicinal Chemistry and Molecular Biology, Merck Research Laboratories, West Point, Pennsylvania 19486.
McKee Sean P
Department of Medicinal Chemistry and Molecular Biology, Merck Research Laboratories, West Point, Pennsylvania 19486.
Thompson Wayne J
Department of Medicinal Chemistry and Molecular Biology, Merck Research Laboratories, West Point, Pennsylvania 19486.
Darke Paul L
Department of Medicinal Chemistry and Molecular Biology, Merck Research Laboratories, West Point, Pennsylvania 19486.
Zugay Joan C
Department of Medicinal Chemistry and Molecular Biology, Merck Research Laboratories, West Point, Pennsylvania 19486.
References (9)
9 references, click to expand
  1. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.
    Science. 1984 May 4;224(4648):500-3 PMID: 6200936
  2. Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease.
    Science. 1990 Aug 3;249(4968):527-33 PMID: 2200122
  3. HIV protease: a novel chemotherapeutic target for AIDS.
    J Med Chem. 1991 Aug;34(8):2305-14 PMID: 1875332
  4. Affinity purification of the HIV-1 protease.
    Biochem Biophys Res Commun. 1989 Nov 15;164(3):955-60 PMID: 2686642
  5. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1.
    Nature. 1989 Feb 16;337(6208):615-20 PMID: 2645523
  6. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).
    Science. 1983 May 20;220(4599):868-71 PMID: 6189183
  7. Structure-based, C2 symmetric inhibitors of HIV protease.
    J Med Chem. 1990 Oct;33(10):2687-9 PMID: 2213822
  8. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease.
    Science. 1989 Aug 11;245(4918):616-21 PMID: 2548279
  9. Active human immunodeficiency virus protease is required for viral infectivity.
    Proc Natl Acad Sci U S A. 1988 Jul;85(13):4686-90 PMID: 3290901
Article Info
Journal
The Journal of organic chemistry
Abbr.
J Org Chem
ISSN
1520-6904
Published
1993-02-00
Pages
1025-1029
Language
English
Region
United States
NLM ID
2985193R
PMCID
PMC6177225
Grants
NIGMS NIH HHS · R01 GM053386 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com